Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: A randomized placebo-controlled trial

Immacolata Capasso, Emanuela Esposito, Nicola Maurea, Maurizio Montella, Anna Crispo, Michelino De Laurentiis, Massimiliano D'Aiuto, Giuseppe Frasci, Gerardo Botti, Maria Grimaldi, Ernesta Cavalcanti, Giuseppe Esposito, Alfredo Fucito, Giuseppe Brillante, Giuseppe D'Aiuto, Gennaro Ciliberto

Research output: Contribution to journalArticle

Abstract

Background: Inositol has been reported to improve insulin sensitivity since it works as a second messenger achieving insulin-like effects on metabolic enzymes. The aim of this study was to evaluate the inositol and alpha lipoic acid combination effectiveness on metabolic syndrome features in postmenopausal women at risk of breast cancer.Methods: A six-month prospective, randomized placebo-controlled trial was carried out on a total of 155 postmenopausal women affected by metabolic syndrome at risk of breast cancer, the INOSIDEX trial. All women were asked to follow a low-calorie diet and were assigned randomly to daily consumption of a combination of inositol and alpha lipoic acid (77 pts) or placebo (78 pts) for six months. Primary outcomes we wanted to achieve were both reduction of more than 20% of the HOMA-IR index and of triglycerides serum levels. Secondary outcomes expected were both the improvement of high-density lipoprotein cholesterol levels and the reduction of anthropometric features such as body mass index and waist-hip ratio.Results: A significant HOMA-IR reduction of more than 20% was evidenced in 66.7% (P

Original languageEnglish
Article number273
JournalTrials
Volume14
Issue number1
DOIs
Publication statusPublished - Aug 28 2013

Keywords

  • Alpha lipoic acid
  • Breast cancer
  • HDL cholesterol
  • Inositol
  • Insulin resistance
  • Metabolic syndrome

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: A randomized placebo-controlled trial'. Together they form a unique fingerprint.

  • Cite this